UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors [Yahoo! Finance]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Yahoo! Finance
UroGen Pharma Ltd. Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche available at Company's discretion until June 30, 2027 PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, announced it has entered into an agreement with funds managed by Pharmakon Advisors, LP (Pharmakon) to revise the terms of its loan agreement entered into in March 2024. On February 26, 2026, the Company entered into an amended and restated loan agreement with funds managed by Pharmakon for a senior secured term loan of up to $250 million in two tranches. The first tranche of $200 million was funded at clo
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- Urogen Pharma Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- UroGen (URGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.MarketBeat
- UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
URGN
Earnings
- 3/2/26 - Beat
URGN
Sec Filings
- 3/2/26 - Form 10-K
- 3/2/26 - Form 8-K
- 3/2/26 - Form 8-K
- URGN's page on the SEC website